OSI’s Oncology research is focused on understanding the science of the EMT in solid tumors in order to develop more effective and safe mechanism-based therapeutic agents. OSI believes that understanding the science of EMT will profoundly impact how MTTs will be combined in the clinic and will lead to the successful development of rational combinations of MTTs in cancer. OSI’s Oncology research team strives to be a world leader in the development of Molecular Targeted Therapies for the treatment of cancer through exploiting the science underpinning Epithelial Mesenchymal Transition.